| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Codeine phosphate [gastro-intestinal use] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 15mg/5mL linctus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 15mg/5mL diabetic linctus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 3mg/5mL pediatric linctus (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 15mg/5mL s/f linctus |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate [analgesic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 15 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 25mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| phosphate de codéine 60 mg/mL, ampoule de 1 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate powder (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 4.56mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 5mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin + carisoprodol + codeine phosphate 325mg/200mg/16mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetaminophen + alcohol + codeine phosphate 120mg/7%vv/12mg elixir |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetaminophen + codeine phosphate 120mg/12mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetaminophen+codeine phosphate 300mg/30mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate + promethazine hydrochloride 10mg/6.25mg syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate + pseudoephedrine hydrochlorid + triprolidine hydrochloride 10mg/30mg/1.25mg liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 30mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Brompheniramine maleate+codeine phosphate+phenylpropanolamine hydrochloride 2mg/5mL 10mg/5mL 12.5mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Aspirin 325 mg and carisoprodol 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and carisoprodol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and butalbital and caffeine and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetaminophen + alcohol + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing butalbital and caffeine and codeine phosphate and paracetamol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing aspirin and carisoprodol and codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate + promethazine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Brompheniramine maleate+codeine phosphate+phenylpropanolamine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate + pseudoephedrine hydrochloride + triprolidine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate+kaolin 10mg/3g/10mL mixture |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Paracetamol+codeine phosphate 500mg/30mg/sachet powder (substance) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 60 mg and paracetamol 1 g effervescent powder for oral suspension sachet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetaminophen + codeine phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Co-codamol 8mg/500mg dispersible tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release effervescent oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 8 milligram and paracetamol 500 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 12.5 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate 12.8 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ibuprofen+codeine phosphate 300mg/20mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fioricet with codeine 325mg/50mg/40mg/30mg capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing codeine and guaifenesin and pseudoephedrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Codeine phosphate hemihydrate (substance) |
Is a |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 13.5 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 15 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Acetaminophen+codeine phosphate 300mg/30mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Acetaminophen+codeine phosphate 300mg/30mg tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely codeine phosphate 30 milligram and paracetamol 500 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Codeine phosphate 15 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 15 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 30 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 30 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 60 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 12.8 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 12.8 mg and ibuprofen 200 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Acetaminophen+codeine phosphate 300mg/30mg tablet |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely codeine phosphate 60 milligram and paracetamol 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Codeine phosphate 30 mg and paracetamol 500 mg oral capsule |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
4 |
| Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 12.8 mg and paracetamol 500 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 12.5 mg and ibuprofen 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 12.5 mg and ibuprofen 200 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 15 mg and paracetamol 500 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Product containing precisely aspirin 325 milligram and butalbital 50 milligram and caffeine 40 milligram and codeine phosphate 30 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin + carisoprodol + codeine phosphate 325mg/200mg/16mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin + carisoprodol + codeine phosphate 325mg/200mg/16mg tablet |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Butalbital 50 mg and caffeine 40 mg and codeine phosphate 30 mg and paracetamol 325 mg oral capsule |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate hemihydrate (substance) |
Is modification of (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetaminophen 300 mg and caffeine 15 mg and codeine phosphate 30 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
| Caffeine 15 mg and codeine phosphate 15 mg and paracetamol 300 mg oral tablet |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 20 mg and ibuprofen 300 mg prolonged-release oral tablet |
Has basis of strength substance (attribute) |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 20 mg and ibuprofen 300 mg prolonged-release oral tablet |
Has precise active ingredient |
True |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
| Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
Has precise active ingredient |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Codeine phosphate 30 mg and paracetamol 500 mg effervescent oral tablet |
Has basis of strength substance (attribute) |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
| Aspirin + carisoprodol + codeine phosphate 325mg/200mg/16mg tablet |
Has precise active ingredient |
False |
Codeine phosphate |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]